programmed death-ligand 1 ligand-iridium(III) complex conjugate

Programmed death-ligand 1 ligand-iridium(III) complex conjugates are an early preclinical series of **triazine-based small-molecule PD-L1 ligand–Ir(III) conjugates** designed for selective delivery of an anticancer iridium(III) complex to PD-L1-expressing non-small cell lung cancer cells. In an AACR 2026 report, conjugate 3 enhanced peripheral blood mononuclear cell recognition and killing of tumor cells, induced endoplasmic-reticulum stress-associated calreticulin exposure, increased mitochondrial reactive oxygen species, and promoted release of immunogenic cell-death signals including ATP and HMGB1. Activity was reduced in PD-L1-knockout cells, supporting PD-L1-dependent tumor-cell delivery. No INN, sponsor development code, clinical formulation, manufacturer, or registered clinical trial has been identified for this conjugate series.

Other names

PD-L1 ligand-Ir(III) complex conjugateprogrammed death-ligand 1 ligand-iridium(III) complex conjugate